What medications are recommended for treating dry eye in an adult patient?

Medications for Dry Eyes

Start with preservative-free artificial tears for all patients, and escalate to anti-inflammatory therapy (cyclosporine 0.05% or lifitegrast 5%) for moderate-to-severe disease, with short-term topical corticosteroids as needed for acute flares.

Treatment Algorithm by Disease Severity

Mild Dry Eye

• Preservative-free artificial tears are the foundation of treatment 1
  • Use these when symptoms require more than 4 times daily application
  • Preserved formulations acceptable for less frequent use, but chronic use demands preservative-free options to avoid toxicity
  • Most artificial tears have comparable efficacy, though study designs vary significantly 1

Critical caveat: Address contributing factors like blepharitis or meibomian gland dysfunction simultaneously—these must be treated or tear substitutes alone will fail 1

Moderate-to-Severe Dry Eye

Add anti-inflammatory therapy to artificial tears 1:

First-line Anti-inflammatory Options:

Cyclosporine 0.05% (FDA-approved)

• Inhibits T-cell activation and inflammatory cytokine production 1
• Demonstrated success rates: 74% (mild), 72% (moderate), 67% (severe) 1
• Expect 10mm improvement in Schirmer test in 15% of patients vs 5% with vehicle 1
• Important limitation: A 2019 Cochrane review (30 RCTs, 4,009 participants) found inconsistent evidence for symptom improvement, though it may increase conjunctival goblet cells 1
• Common side effect: ocular burning in 17% of patients 1
• After 1 year of twice-daily therapy, can reduce to once daily in some patients 1

Lifitegrast 5% (FDA-approved 2016)

• Blocks LFA-1/ICAM-1 interaction, preventing T-cell activation 1
• Shows benefit in both signs (corneal/conjunctival staining) and symptoms (dryness, discomfort) over 3 months 1
• Safe through 12 months, though long-term effects unknown 1

Both cyclosporine and lifitegrast are FDA-approved and represent equivalent first-line anti-inflammatory choices—select based on patient tolerance and cost considerations.

Adjunctive Corticosteroid Therapy:

Topical corticosteroids (e.g., loteprednol etabonate 0.25%) for short-term use 1

• Use for several weeks only to suppress acute inflammation
• Reduces ocular irritation, decreases corneal fluorescein staining, improves filamentary keratitis 1
• 2-week courses show benefit in symptoms and conjunctival hyperemia 1
• Mandatory monitoring: Check intraocular pressure and monitor for cataract formation 1
• Consider as bridge therapy or for acute exacerbations

Recent evidence supports aggressive dual therapy: Combining high-potency steroids with cyclosporine 0.05% significantly improved both signs and symptoms in severe DED compared to cyclosporine alone, without increased glaucoma or cataract risk 2

What NOT to Recommend

Oral omega-3 fatty acid supplements: A large-scale, masked, prospective study found no benefit over placebo at 12 months in moderate-to-severe dry eye 1. While some reports suggest benefit in blepharitis as adjunctive therapy, the evidence is inconsistent and formulations are unstandardized 1.

Post-Surgical Considerations

After cataract surgery or other ocular procedures, escalate therapy aggressively 3:

• Preservative-free artificial tears (increased frequency)
• Topical steroids and NSAIDs (first month)
• Consider punctal plugs, autologous serum, or cyclosporine as needed beyond 1 month 3

Common Pitfalls to Avoid

1. Using preserved artificial tears chronically—this damages the ocular surface and worsens disease
2. Failing to treat concurrent blepharitis/meibomitis—these must be addressed or dry eye therapy will fail
3. Prolonged corticosteroid use without IOP monitoring—risk of glaucoma and cataracts
4. Expecting immediate results from cyclosporine—benefits may take weeks to months
5. Recommending omega-3 supplements as primary therapy—evidence does not support this

Emerging Therapies

The recent FDA approval of AR-15512 (TRPM8 agonist) represents a new mechanism-specific approach targeting neurosensory dysfunction 4. Novel drug delivery platforms (nanomicelles, mucus-penetrating particles) are improving bioavailability and reducing adverse effects 4.